Cancer immunotherapy continues to have a great impact on clinical practice in oncology as it enabled effective treatment of previously refractory neoplasms by activation of the immune response. Blockade of inhibitory immune checkpoint molecules shifts the balance toward antitumor immunity which allows more effective control of tumor growth and improves clinical outcomes [1]. Immune checkpoint molecules maintain immunologic homeostasis and play an important role in T-cell maturation and regulation of peripheral tolerance to prevent autoimmune responses.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...